Newsletter Signup | Join Community
Answers to frequently asked questions about Ovarian Germ Cell cancers
Answers to frequently asked questions about CA 125.
Combination of novel precision cancer medicines represents future direction of ovarian cancer treatment.
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Stay Current With Ovarian Cancer Treatment Advances & Connect with Others
Hospital and surgeon experience contribute to lower mortality rates and better outcomes for ovarian cancer.
Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer
Research suggests new immunotherapy combination treatment is promising for ovarian cancer.
Treatment of Stage III Ovarian Cancer
Learn about the NOCC mission and support programs.
Dr. Ritu Salani M.D. The Ohio State – Arthur G. James Cancer Hospital Discusses Ovarian Cancer Survivorship
Dr. Matulonis, of the Medical Gynecologic Oncology Program answers questions about cervical and uterine cancer
CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Garber.
Ask the Experts Series:
Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient
Cancer Connect - Treatment of Stage I Ovarian Cancer
Treatment of Stage IV Ovarian Cancer
Treatment of Stage II Ovarian Cancer
AFCR Scientists Uncovered Potential New Treatment for Ovarian Cancer
Oral Contraceptives Reduce Risk for Ovarian and Endometrial Cancers
Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer
During cytoreductive surgery, physicians attempt to remove as much of the ovarian cancer as possible.
Q: What is an ovarian germ cell tumor?
Dr. Birrer M.D. of Mass General Hospital answers common questions about clinical trials for ovarian cancer.
Dr. Sarah F. Adams, MD, The Victor and Ruby Hansen Surface Professor in Ovarian Cancer Research provides an update.
Roswell Park Cancer Institute Experts Discuss Ovarian Cancer Research, Immunotherapy, and Personalized Medicine
Personalized Screening Test for Ovarian Cancer Potentially Game-Changing, says GlobalData
Vaccines Stimulating Immune System Produce Responses in Advanced Cervical and Ovarian Cancers
T-Cells Can be Directed to Treat a Variety of Ovarian Cancers
SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment
FDA Warns Against Ovarian Cancer Screening Tests
Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine
Ovarian cancer survivors share their stories to provide inspiration and encourage awareness of early detection.
10 Things Every Woman Should Know About Ovarian Cancer
FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer
FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer
Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer
Intraperitoneal Chemotherapy Underused in Ovarian Cancer
Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer
Cediranib Improves Survival in Recurrent Ovarian Cancer
Annual meeting brings together cancer experts from around the world.
New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer.
Delaying Treatment Increases Mortality in Ovarian Cancer
Novel Two-step Immunotherapy Shows Promise in Recurrent Ovarian Cancer
Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival in Recurrent Platinum-Sensitive Ovarian Cancer
Dr. Chi and Dr. Bell-McGuinn from Memorial Sloan-Kettering Cancer Center Discuss Treatment Options for Ovarian Cancer.
Ovarian Cancer Rates Appeared to Drop Along with a Drop in the Use of Hormone Replacement Therapy
Ovarian Cancer Rates Declining in Breast Cancer Survivors
Smoking Increases Risk of Mucinous Ovarian Cancer
Referred to as “the silent killer,” ovarian cancer is often diagnosed in the advanced stages, when a cure is unlikely.
National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer.
BRCA Genes May Influence Ovarian Cancer Outcomes
Genetic Testing For Women at High Risk of Ovarian Cancer
BRCA Mutations Influence Ovarian Cancer Outcomes
Ovarian Cancer National Alliance
Aspirin May Reduce Risk of Serous Ovarian Cancer
Eye on the Prize
Avastin Delays Progression of Ovarian Cancer But May Not Improve Overall Survival.
Advances in the screening, early detection and treatment of ovarian cancer.
Issues Ovarian Cancer Patients Face
Four Points to Remember About Heredity and Ovarian Cancer
AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer
Gradalis Announces a Novel Combination Study of Vigil® EATC in Women with Advanced Ovarian Cancer
OVA1 Detects More Ovarian Cancers than CA 125.
Screening with CA-125 and Ultrasound Does Not Reduce Ovarian Cancer Mortality
Cabozantinib Shows Promise against Bone Metastases
Avastin Shows Benefit in Ovarian Cancer
Screening & Prevention of Ovarian Cancer
AMG 386 Shows Promise Against Recurrent Ovarian Cancer.
BRCA-Related Cancers Diagnosed at Younger Age in Subsequent Generations
Fertility Drugs Do Not Increase Risk of Ovarian Cancer
Women commonly report symptoms to their primary care provider during the year before a diagnosis of ovarian cancer.
One Step Closer to Early Detection of Ovarian Cancer
Addition of Hycamtin Doesn’t Improve Outcomes in Newly Diagnosed Ovarian Cancer
Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer
Chemotherapy Improves Survival in Women with Stage I Ovarian Cancer
Surgery May Improve Survival Compared to Chemotherapy in Patients with Recurrent Ovarian Cancer
Search for Early Markers of Ovarian Cancer Continues
Chemotherapy Drug Patupilone Fails in Advanced Ovarian Cancer
Genetic Testing Recommendations by Physicians Don’t Always Follow Guidelines
Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
Hormone Replacement Therapy after Ovary Removal May be Safe for BRCA1/BRCA2 Carriers.
Farletuzumab Shows Promise in Relapsed Ovarian Cancer
Fertility Preservation Appears to Be Safe for Young Women with Early-stage Ovarian Cancer
For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon
Tests Detect Ovarian Cancer at Early Stage, But Benefits Still Uncertain
False-positive Results Are Common with Cancer Screening
Obesity Linked with Increased Risk of Ovarian Cancer
Alimta® Active Against Platinum-resistant Ovarian Cancer
Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer
Cancer Caregivers Devote Substantial Time and Effort
Preventive Removal of the Ovaries and Fallopian Tubes Reduces Risk of Breast, Ovarian, and Fallopian Tube Cancers
Ovarian cancer symptoms, risk factors, and treatment
Blood Test and Symptoms Help Detect Ovarian Cancer
The Gynecologic Oncology Group: Advancing The Prevention And The Treatment Of Gynecologic Cancers
Women Share Breast and Ovarian Cancer Testing Results with Family Members
Women with Ovarian Cancer Receive Optimal Treatment from High-volume Specialists.
Oral Contraceptives Reduce Risk of Ovarian Cancer
Quality of Life Assessed for Intraperitoneal Chemotherapy in Ovarian Cancer
Statins at Time of Surgery May Improve Survival in Ovarian Cancer
Combination of Biomarker Tests Highly Accurate in Detecting Ovarian Cancer
Gene Helps Predict Response to Chemotherapy in Ovarian Cancer
Hormone Therapy Increases Ovarian Cancer Risk
Fluctuation in Weight May Influence Risk for Ovarian Cancer
Perceptions of Ovarian Cancer Influence Decisions Regarding Prophylactic Oophorectomy
Women Encouraged to Watch for Ovarian Cancer Warning Signs
Addition of Ellence® to Standard Chemotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Intraperitoneal Hyperthermic Chemotherapy May Improve Survival in Ovarian Cancer
Caffeine Associated with Lower Risk of Ovarian Cancer
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists
Dietary Flavonoids Reduce Risk of Ovarian Cancer
HRT Linked to Ovarian Cancer
Elderly Should Receive Same Therapy for Ovarian Cancer as Younger Patients.
Gemzar® and Doxil® Similarly Effective Against Platinum-resistant Ovarian Cancer
Oophorectomy Linked with Cognitive Problems
Further Evidence Suggesting Survival Associated with Surgeon Experience in Ovarian Cancer.
Low-fat Diet Reduces Risk of Ovarian Cancer.
Postmenopausal Hormones Linked with Increased Risk of Ovarian Cancer
Avastin® May Provide Benefit in Recurrent Ovarian Cancer
Avastin® Effective for Recurrent Ovarian Cancer
Gynecologic Oncologists Offer High-Quality Care for Ovarian Cancer
Low-dose Contraceptives Reduce Risk of Ovarian Cancer
Doxil® plus Eloxatin® Highly Active in Recurrent Ovarian Cancer
Removal of Lymph Nodes Improves Survival in Early Ovarian Cancer
Doxil®/Paraplatin® Effective in Recurrent Ovarian Cancer
Surgery to Remove Recurrent Ovarian Cancer Provides Favorable Survival.
Caring for Yourself During Chemotherapy for Ovarian Cancer: How to Manage Hair Loss, Dry Skin, and Brittle Nails
Women with Family History of Breast or Ovarian Cancer Have Increased Risk of Developing Leukemia.
Avastin Approved by the FDA for Recurrent Ovarian Cancer
Obesity Associated with Decreased Survival in Ovarian Cancer
Results from ChemoFX® Associated with Survival in Ovarian Cancer Patients
Paraplatin®/Cytoxan® a Possible Alternative for Ovarian Cancer
Surgical Removal of Cancer Spread to the Diaphragm Improves Survival in Ovarian Cancer
Minimizing Residual Disease Associated with Improved Survival for Ovarian Cancer
Updated Guidelines for Treatment of Ovarian Cancer